SEC Filings
Merck Is 22% Of Personalis Revenue — And A Related Party Voting For The Tempus Deal
Personalis's largest customer owns more than 10% of its stock, and Tempus fees inside selling costs have jumped to $4.8 million.
SEC Filings
Personalis's largest customer owns more than 10% of its stock, and Tempus fees inside selling costs have jumped to $4.8 million.
SEC Filings
The surgical-robot maker's quarterly report details a class action and a derivative suit, with losses it says it cannot estimate.
SEC Filings
The software maker sold stock at $114.5906 a share to underwriters and five note series with coupons from 7.000% to 8.650%.
SEC Filings
Chairman Kim Cocklin retires at the 2027 annual meeting after more than 20 years, and the board approved the combined job.
SEC Filings
The drug developer held $629.8 million at September 30, before a $2.0 billion AstraZeneca investment closed on October 5.
SEC Filings
Receivables jumped from $3.9 million at year-end, and nine-month operating cash flow is still negative $49.8 million despite profit.
SEC Filings
The vaccine developer's quarterly report shows a 12-year finance lease on its Swiss suite and two PCV21 comparisons that missed the tougher FDA-style test.
SEC Filings
The board named her CEO effective January 4, 2027, ending Bruce Broussard's interim stretch; he becomes chair.
SEC Filings
Oil realized well above last year's prices, and the producer raised its full-year range to 176,000 to 178,000 barrels a day.
SEC Filings
Rain and a conveyor failure cut production, yet cash rose more than fourfold to $1.2 billion and Coeur repurchased $111 million of stock.
SEC Filings
Gross margin fell to about 41% from 49% on seasonal power costs, while bitcoin holdings and per-share holdings each grew about 5%.
SEC Filings
A $39 million tariff refund inflated reported margins, but adjusted operating margin still rose 240 basis points to 20.9%.